Professor of Medicine, Mayo Medical School
Oncology
Dr. Jan C. Buckner, MD
|
|
Give Review
Buckner works in the field of Oncology. He studied medicine at University of North Carolina at Chapel Hill School of Medicine. University of North Carolina at Chapel Hill School of Medicine is a top medical university. University of North Carolina at Chapel Hill School of Medicine is ranked 22 in research and 2 in primary care medicine He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "Best Doctors/Medical Oncology", "DOM Residency-Top Educator", "Minority Medical Student Award-Nicole Marshall", "Mayo Awards for Excellence, Excellence Through Teamwork", "Award for Excellence in Clinical Research", "Carswell Scholar" and "Whos Who in Medicine and Healthcare". Buckner is a published doctor as well. He has 71 publications published. The latest was: Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patie... Buckner accepts Medicare payments and is listed with Medicare.gov.
Publications
- Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
- Clinical outcomes of children and adults with central Nervous system primitive neuroectodermal tumor.
- Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).
- Impact of imaging measurements on response assessment in glioblastoma clinical trials.
- The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic Astrocytoma.
- Long-term Outcomes and Role of Chemotherapy in Adults With Newly Diagnosed Medulloblastoma.
- New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled Analysis of EORTC/RTOG/NC...
- Changes in presentation, treatment, and outcomes of adult low-grade Gliomas over the past fifty years.
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial.
- Presentation, management, and outcome of newly diagnosed glioblastoma in elderly patients.
- Gliomatosis cerebri: clinical characteristics, management, and outcomes.
- Conditional probability of long-term survival in glioblastoma: A population-based Analysis.
- Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic Astrocytoma.
- Long-Term Outcome of Esthesioneuroblastoma: Hyams Grade Predicts Patient Survival.
- A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and Astrocytomas with IDH1 or IDH2 mutation.
- Associations of High-Grade Glioma With Glioma Risk Alleles and Histories of Allergy and Smoking.
- Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
- Validation of EORTC Prognostic Factors for Adults With Low-Grade Glioma: A Report Using Intergroup 86-72-51.
- Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
- Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious ...
- North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Patients with Newly Diagnosed...
- Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
- Long-term follow-up of dose-adapted and reduced-field radiotherapy with or without chemotherapy for central Nervous system germinoma.
- Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Gr...
- Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced Cancer.
- Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize.
- Joint NCCTG and NABTC prognostic factors Analysis for high-grade recurrent glioma.
- Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma.
- Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
- Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central Cancer treatment group ...
- Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central Cancer treatment group study.
- Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group...
- Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial.
- Malignant primary cardiac Tumors: review of a single institution experience.
- A prospective study of quality of life in adults with newly diagnosed high-grade Gliomas: comparison of patient and caregiver ratings of quality of life.
- Validation of single-item linear Analog scale assessment of quality of life in neuro-oncology patients.
- Central Nervous system tumors.
- Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
- Innovation in the management of Brain metastases.
- Central neurocytoma: management recommendations based on a 35-year experience.
- The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
- Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.
- A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
- A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced Cancer.
- Validation of neuroradiologic response assessment in Gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume ...
- Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.
- Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.
- GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials.
- Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial.
- A prospective study of quality of life in adults with newly diagnosed high-grade Gliomas: the impact of the extent of resection on quality of life and survival.
- Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 Astrocytoma (anaplastic Astrocytoma): results of North Central...
- Current issues in diagnosis and treatment of primary and metastatic Brain tumors.
- Immunohistochemical detection of EGFRvIII in high malignancy grade Astrocytomas and evaluation of prognostic significance.
- Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic Astrocytoma: final report of ...
- Factors influencing survival in high-grade Gliomas.
- Management of Brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years.
- Unusual presentation of adult metastatic peritoneal Medulloblastoma associated with a ventriculoperitoneal shunt: a case study and review of the literature.
- Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination.
- The neurocognitive effects of radiation in adult low-grade glioma patients.
- Hemangiopericytoma in the central Nervous system: treatment, pathological features, and long-term follow up in 38 patients.
- Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
- Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoAstrocytoma: efficacy and associati...
- Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with Malignant melanoma.
- Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade Astrocytomas.
- Phase II trial of gemcitabine in advanced sarcomas.
- Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade Gliomas.
- Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorub...
- Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal Tumors ...
- Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patie...
Schools
University Of North Carolina Chapel Hill School Of Medicine
Butterworth Hospital
Mayo Clin
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Best Doctors/Medical Oncology
- DOM Residency-Top Educator
- Minority Medical Student Award-Nicole Marshall
- Mayo Awards for Excellence, Excellence Through Teamwork
- Award for Excellence in Clinical Research
- Carswell Scholar
- Whos Who in Medicine and Healthcare
Education
-
Mayo School of Graduate Medical Education -
University of North Carolina at Chapel Hill School of Medicine -
Wake Forest University
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1235115262 | |
| NPPES Provider LastName | BUCKNER | |
| NPPES Provider FirstName | JAN | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 33.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235115262 |
| Last Name Of The Provider | BUCKNER |
| First Name Of The Provider | JAN |
| View All |
Similar Doctors
|
|
Dr. Gary A. Croghan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick A. Burch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prema P. Peethambaram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Moynihan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynn C. Hartmann, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|